Perspective Therapeutics Divests Brachytherapy Business
December 12, 2023 08:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced it agreed to fully divest its brachytherapy...
Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine Tumors
December 07, 2023 08:00 ET
|
Perspective Therapeutics, Inc.
First U.S. patient with refractory or relapsed SSTR2-positive neuroendocrine tumors treated with [212Pb]VMT-α-NETPreliminary data readout expected in second half of 2024 SEATTLE, Dec. 07, 2023 ...
Perspective Therapeutics Announces First Ever Human SPECT Imaging of Pb-212 with VMT-α-NET by Clinical Collaborators in Germany
November 28, 2023 08:00 ET
|
Perspective Therapeutics, Inc.
Imaging was conducted as part of a clinical study at Technical University of Dresden in GermanyImage was selected as “Image of the Month” in the European Journal of Nuclear Medicine and Molecular...
Perspective Therapeutics Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals
November 27, 2023 08:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced the publication of four preclinical studies in support of the Company’s...
Perspective Therapeutics Completes Initial Dose Escalation Cohort for Second Novel Targeted Alpha Therapy
November 16, 2023 08:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced the completion of cohort 1 dosing in the Phase 1/2a clinical trial of...
Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights
November 14, 2023 16:25 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced third quarter financial results for the period ended September 30, 2023 and provided...
Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Study of [(212)Pb]VMT-α-NET for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors
November 08, 2023 08:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announced today that the first patient was dosed at Washington...
Perspective Therapeutics Completes Recruitment for First Patient Cohort in Phase 1/2a Dose Escalation Trial of VMT01 in Malignant Melanoma
October 16, 2023 08:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced the completion of recruitment for the first patient...
Perspective Therapeutics’ VMT-α-NET Protocols Presented at the North American Neuroendocrine Tumor Society (NANETS) 2023 Symposium
October 10, 2023 08:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that two upcoming investigator-initiated trials...
Perspective Therapeutics’ Cesium-131 Featured at the American Society for Radiation Oncology’s Annual Conference
October 05, 2023 16:05 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and...